Schistosoma Haematobium Clinical Trial
Official title:
Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children
Objectives:To reduce the risk of S. haematobium pathology recurrences during the three years
following vaccine administration and to control the safety of this therapeutic strategy in
children exposed to urinary schistosomiasis.
Methodology : Phase III trial, self-contained, randomized, double blind, in two parallel
groups receiving 3 injections at D0, W4, W8 and a boost at W52, one group receiving
"Bilhvax", the other one placebo, in S. haematobium infected children pretreated by two
doses of PZQ (at W9 and W8) Patient included : Infected school children, 6 to 9 years of
age.
Primary objective : To demonstrate a significant delay of recurrence of the schistosomiasis
pathology in vaccine group compared to control group in the 3 years period following the
first administration (between D0 and W152).
Secondary objective : safety
Duration : February 2009 to March 2012
Patient inclusion (detailed criteria):
Children in CI or CP classes of public schools in St Louis Region (Senegal) A male or female
between, and including, 6 and 9 years of age at the time of the first vaccination Free of
obvious health problems excepted schistosomiasis as established by clinical examination
(W8-W1) Found positive for S. haematobium infection during the selection period (W12 à W9) :
microhaematuria ≥ 2+ et Urinary Filtration, UF ≥ 50 eggs of Sh/10ml urine Written inform
consent obtained from the parent or guardian of the subject (W9) and child acceptance
Pretreated with 2 doses of 40mg/kg PZQ (at W9 and W8) Absence of heavy lesions of the
urinary tract under echotomography (W8 et W1)
Primary objective (detailed):
To demonstrate a significant delay of recurrence of the schistosomiasis pathology in vaccine
group compared to control group in the 3 years period following the first administration
(between D0 and W152).
Criterion of meeting the recurrence is the association of :
Positive microscopic haematuria (positivity by urinary stick : ≥ 1+)
- either during the active visits (W82, W100, W117, W134, or W152).
- or after spontaneous complaint of the patient at any time Positive parasitological test
defined as the presence of at least one living egg of S. haematobium during one out of
three UF (one UF per day/3 days during one week). The delay of the first recurrence is
defined as the delay between the date of inclusion and the date of the positive
parasitological test.
Statistical considerations : The number of patients necessary to detect the expected
difference after 3 years of study (50% of recurrence in vaccinated group versus 70% in
placebo group), with a statistical power of 80% and a bilateral test at 5%, is 103 children
per group. To assume the lost of statistical power in the "intention to treat" analysis
(ITT) resulting from the number of cases where vaccine protocol has not been completed, 125
children per group will be included in the study. In total 250 children will be included in
the study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03893097 -
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
|
Phase 3 | |
Not yet recruiting |
NCT05941884 -
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.
|
||
Withdrawn |
NCT02810613 -
Leiden University Medical Center Mini Donor Bank
|
N/A | |
Completed |
NCT00510159 -
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
|
Phase 2/Phase 3 | |
Completed |
NCT00713999 -
Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar
|
N/A | |
Completed |
NCT01163877 -
Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma
|
N/A |